Praeruptorin A: Multi-Target Pyranocoumarin for Inflammation and Cancer Research

Executive Summary: Praeruptorin A is an angular pyranocoumarin compound isolated from Peucedanum praeruptorum Dunn with a defined structure (C₂₁H₂₂O₇, MW 386.40). It inhibits ferroptosis by regulating DMT1-mediated Fe²⁺ influx, blocks STAT-1/3 and NF-κB signaling, and downregulates MMP1 via ERK1/2 pathway modulation (APExBIO). The compound suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and upregulates anti-inflammatory mediators (IL-10, TGF-β) in preclinical models. Praeruptorin A demonstrates low cytotoxicity and no observable multi-organ damage at effective in vivo doses. Its multi-targeted activity is relevant for cancer biology, ulcerative colitis, and cardiomyopathy research (Lin et al., 2021).

Biological Rationale

Praeruptorin A belongs to the angular pyranocoumarin class, structurally characterized by a fused pyran ring and coumarin core (APExBIO). It is derived from traditional Chinese medicinal plants, notably Peucedanum praeruptorum Dunn. Its biological activity profile is distinguished by simultaneous modulation of iron transport (DMT1), inflammatory signaling (STAT-1/3, NF-κB), and extracellular matrix remodeling (MMP1 via ERK1/2).

Unlike single-pathway inhibitors, Praeruptorin A acts on multiple therapeutic targets. This polypharmacology makes it a valuable tool in dissecting complex disease networks, such as the interplay between inflammation, ferroptosis, and cancer metastasis (see related review—this article extends with new safety and dosing details for translational setups).

• DMT1 inhibition reduces Fe²⁺-induced oxidative stress and ferroptosis.
• STAT-1/3 and NF-κB pathway suppression modulates inflammatory cytokine expression.
• Downregulation of MMP1 limits extracellular matrix degradation and cell migration.

Mechanism of Action of Praeruptorin A

Praeruptorin A exerts its effects via several interlocking molecular mechanisms:

• DMT1 Inhibition: Decreases iron overload and prevents ferroptosis in cardiomyocytes and cancer cells (Lin et al., 2021).
• STAT-1/3 Signaling Inhibition: Blocks phosphorylation of STAT-1/3, reducing transcription of pro-inflammatory mediators.
• NF-κB Pathway Suppression: Inhibits nuclear translocation and activation of NF-κB (p65), lowering TNF-α, IL-6, and IL-1β expression.
• ERK1/2 Pathway Modulation: Downregulates MMP1, inhibiting cell migration and invasion in hepatocellular carcinoma models.
• Barrier Protein Restoration: Upregulates ZO-1, occludin, and claudin-1, supporting intestinal barrier integrity in ulcerative colitis models.
• Regulation of Downstream Targets: Modulates IL-10, TGF-β (anti-inflammatory), HMOX1, PTGS2, and cholesterol transporter Abca1.

These mechanisms are supported by transcriptomic, biochemical, and functional assays. Integrated pathway analysis demonstrates convergence on inflammation and ferroptosis regulation (systems biology perspective—this article adds in vivo benchmarks and solution parameters).

Evidence & Benchmarks

• Praeruptorin A (0.4–10 μM) inhibits DMT1-mediated Fe²⁺ uptake and rescues cardiomyocytes from doxorubicin-induced ferroptosis (Lin et al., 2021).
• Suppresses STAT-1/3 phosphorylation and NF-κB activation, reducing pro-inflammatory cytokines in murine colitis models (effective at 0.8–1.2 mg/kg/day i.p. and 30 mg/kg/day oral) (APExBIO).
• Downregulates MMP1 via ERK1/2, limiting migration and invasion of hepatocellular carcinoma cells in vitro (concentration range: 1–75 μg/mL) (mechanistic review—here we include comparative safety data and full solubility notes).
• No significant cytotoxicity or evidence of multi-organ damage at research doses in mice (APExBIO).
• Restores intestinal barrier proteins (ZO-1, occludin, claudin-1) and alleviates colonic apoptosis in ulcerative colitis models (molecular review—this article details multiparametric outcome data).

Applications, Limits & Misconceptions

Applications:

• Ulcerative Colitis Research: Praeruptorin A restores epithelial barrier function and suppresses inflammatory cytokine cascades (Lin et al., 2021).
• Cancer Biology: Inhibits cancer cell migration, invasion, and enhances doxorubicin antitumor activity.
• Cardiomyopathy Models: Reduces iron-induced myocardial injury and ferroptotic cell death (APExBIO).

Limits: Efficacy is cell-type and context-dependent. Water insolubility requires organic solvents for preparation. Human pharmacokinetics are uncharacterized. Over-interpretation beyond preclinical models is discouraged.

Common Pitfalls or Misconceptions

• Praeruptorin A is not water-soluble; DMSO or ethanol must be used for stock preparation (≥50.8 mg/mL in DMSO; ≥12.68 mg/mL in ethanol with sonication).
• It is not a pan-cytotoxic agent; lacks broad cytotoxicity at tested concentrations.
• Data for human clinical use are lacking; all efficacy claims are preclinical.
• Over-interpretation of single-pathway effects is incorrect; activity is multi-target.
• Solutions should not be stored long-term; compound is sensitive to light and temperature (store at 4°C, shielded).

Workflow Integration & Parameters

Source and Handling: Praeruptorin A (SKU N2885) is distributed by APExBIO. For in vitro assays, dissolve in DMSO (≥50.8 mg/mL) or ethanol (≥12.68 mg/mL, sonicated). The compound is insoluble in water. Prepare fresh solutions, avoid long-term storage, and protect from light.

Experimental Dosing:

• In vitro: 0.4 μM–75 μg/mL, variable by cell line.
• In vivo (murine): 0.8–1.2 mg/kg/day i.p.; 30 mg/kg/day p.o.

Controls: Always include solvent control. Confirm cell-type-specific responses. For signaling studies, use validated antibodies for DMT1, STAT-1/3, NF-κB (p65), and ERK1/2.

Interlink: For advanced mechanistic guidance, see Praeruptorin A: Mechanistic Insights and Research Frontiers (this article updates with detailed solution handling and new in vivo safety data).

Conclusion & Outlook

Praeruptorin A is a validated multi-pathway inhibitor for preclinical research in inflammation, ferroptosis, and cancer metastasis. It offers robust in vitro and in vivo activity, with a favorable safety profile and clear solvent/handling specifications. APExBIO's N2885 kit provides a standardized source for experimental reproducibility. Further studies, especially on human pharmacokinetics and long-term safety, are warranted. For systems biology and translational workflows, Praeruptorin A integrates well with multi-omics and network pharmacology platforms (see systems review—this article clarifies dosage and safety benchmarks).